Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
Design and rationale for MAGNITUDE, a phase 3, randomized, placebo-controlled trial of NTLA2001, a CRISPR-based gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy (ATTR- CM)
ÌÇÐÄ´«Ã½
Design and rationale for MAGNITUDE, a phase 3, randomized, placebo-controlled trial of NTLA2001, a CRISPR-based gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy (ATTR- CM) Maurer, M. S., Fontana, M., Claggett, B., Hernandez, A., Januzzi, J. L., Lam, C., Lewis, E., Garcia-Pavia, P., Shah, S. J., Solomon, S., Gutstein, D., Pickard, M. D., Anderson, L., Olbertz, J. TAYLOR & FRANCIS LTD. 2024: S60View details for